Sameena Rahman
Obstetrics & Gynecology · Commerce, CANPI 1093896573
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (58.4%), consulting fees and education — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Endo USA, Inc. at 40.2% of the total. Reporting peaked in 2024 at $1,912 and has fallen 83.9% since, to $309 in 2025.
Across 111 payments — averaging $39.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Endo USA, Inc.$2K
- Mayne Pharma Commercial LLC$370
- Cosette Pharmaceuticals Inc.$218
- Sumitomo Pharma America, Inc.$211
- AbbVie$191
- Agile Therapeutics, Inc.$186
- plus $1K from 20 others
What the payments were for
- Consulting fees$1,75040%
- Food & beverage$2,54658%
- Education$601%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Endo USA, Inc. | 1 | $1,750 |
| Mayne Pharma Commercial LLC | 23 | $370 |
| Cosette Pharmaceuticals Inc. | 3 | $218 |
| Sumitomo Pharma America, Inc. | 10 | $211 |
| AbbVie(2 entities) | 10 | $191 |
| Agile Therapeutics, Inc. | 9 | $186 |
| Astellas Pharma US Inc | 2 | $158 |
| Therapeuticsmd, Inc. | 7 | $158 |
| Myriad Women's Health, Inc. | 1 | $146 |
| Avion Pharmaceuticals | 8 | $138 |
| Myovant Sciences Inc. | 6 | $136 |
| Bayer | 3 | $75 |
| Lupin Inc. | 3 | $72 |
| Endo Pharmaceuticals Inc. | 1 | $68 |
| Scynexis, Inc. | 3 | $56 |
| Si-bone, Inc. | 3 | $53 |
| Hologic Sales And Service, LLC | 2 | $52 |
| Evofem Biosciences, Inc. | 3 | $49 |
| Abbott | 2 | $48 |
| AMAG Pharmaceuticals, Inc. | 2 | $47 |
| Coopersurgical, Inc. | 2 | $40 |
| Dysis Medical, Inc. | 2 | $37 |
| Millicent US Inc | 2 | $31 |
| Medtronic | 1 | $29 |
| Bioventus LLC | 1 | $21 |
| Gynesonics, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIAFLEX$1,750
- VYLEESI$177
- myRisk$146
- Veozah$125
- NEXTSTELLIS$120
How this compares
$4,356 in reported general payments places this provider in the 85th percentile of 3,784 obstetrics & gynecology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pregabalin | 13 | $919 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Commerce
- Steve YuNorthridge$964K
- Samir HageRedlands$640K
- Malcolm MunroLos Angeles$609K
- Michael KrychmanCosta Mesa$547K
- Anita NelsonTorrance$530K
- Jan SegnitzSan Jose$511K
- Risa KaganBerkeley$497K
- Michael GreenOxnard$424K
- Howard SalvaySanta Cruz$421K
- Marc WinterLaguna Hills$399K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.